Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

This study has been completed.
Array BioPharma
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: July 3, 2013
Last updated: April 8, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)